Lee IC, Lin W-M, Shu J-C, Tsai S-W, Chen C-H, Tsai M-T
Starting in April of this year, Medicare and Medicaid may begin covering GLP-1 medications more broadly, with eligible patients potentially seeing out-of-pocket costs capped at approximately $50 per month
The kynurenine pathway, the periphery, and the gut-brain-axis Peripheral KP metabolism is a critical determinant of MDD pathology, acting as a conduit through which systemic inflammation and metabolic stress influence central neurotransmission and neuroplasticity
Extending the treatment duration from 12 wk to 16, 20, or 24 wk significantly impacted histological outcomes
Can GLP-1 drugs directly cause pancreatitis